Follow
Ben Johnson wrote this piece for Nature Biotech on #Parkinson's - he's my editor over at #NatureMedicine.
"Recent trial failures have called into question the central role of α-synuclein in Parkinson’s disease pathology. Although many continue to target α-synuclein aggregates in the brain, others are paying attention to the endolysosomal pathway, mitochondria and even glucose metabolism."
